Securities Fraud Class Action Filed Against Soleno Therapeutics, Inc.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy SLNO?
Source: PRnewswire
- Lawsuit Background: On March 14, 2026, Kessler Topaz Meltzer & Check, LLP filed a securities fraud class action against Soleno Therapeutics, Inc. for investors who purchased common stock between March 26 and November 4, 2025, highlighting serious concerns regarding the company's financial transparency.
- Safety Concerns Disclosure: The lawsuit alleges that Soleno concealed significant safety issues related to its DCCR drug during Phase 3 clinical trials, including fluid retention in participants, which raised doubts about the drug's commercial viability and negatively impacted the company's market credibility.
- Stock Price Plunge: Following the financial results announcement on November 4, 2025, Soleno's stock price dropped over 26% due to negative revelations linked to the Scorpion Capital report, indicating a pessimistic market sentiment regarding the company's future prospects.
- Investor Action Recommendation: Soleno investors are encouraged to apply for lead plaintiff status in the class action by May 5, 2026, demonstrating their proactive stance in legal rights protection and concern for corporate governance issues.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SLNO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SLNO
Wall Street analysts forecast SLNO stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 36.740
Low
75.00
Averages
110.50
High
125.00
Current: 36.740
Low
75.00
Averages
110.50
High
125.00
About SLNO
Soleno Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of rare diseases. The Company’s lead product candidate, diazoxide choline extended-release tablets (DCCR), is for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. DCCR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. Its proposed mode of action, with targets in the brain, pancreas and fat tissue, has the potential to broadly impact complex diseases like PWS to reduce appetite, reduce food-seeking, decrease insulin and leptin resistance, and reduce body fat. The Company has Breakthrough Therapy and Fast-Track designations in the United States and Orphan Drug designations in the United States and European Union.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Securities Fraud Class Action Filed Against Soleno Therapeutics, Inc.
- Lawsuit Background: On March 14, 2026, Kessler Topaz Meltzer & Check, LLP filed a securities fraud class action against Soleno Therapeutics, Inc. for investors who purchased common stock between March 26 and November 4, 2025, highlighting serious concerns regarding the company's financial transparency.
- Safety Concerns Disclosure: The lawsuit alleges that Soleno concealed significant safety issues related to its DCCR drug during Phase 3 clinical trials, including fluid retention in participants, which raised doubts about the drug's commercial viability and negatively impacted the company's market credibility.
- Stock Price Plunge: Following the financial results announcement on November 4, 2025, Soleno's stock price dropped over 26% due to negative revelations linked to the Scorpion Capital report, indicating a pessimistic market sentiment regarding the company's future prospects.
- Investor Action Recommendation: Soleno investors are encouraged to apply for lead plaintiff status in the class action by May 5, 2026, demonstrating their proactive stance in legal rights protection and concern for corporate governance issues.
See More
ASP Isotopes Class Action Survives Dismissal Motion
- Class Action Progress: The class action against ASP Isotopes Inc. (NASDAQ: ASPI) survives a partial dismissal motion in the Southern District of New York, indicating that securities fraud allegations against the company and its executives remain valid, potentially exposing the company to significant legal liabilities.
- False Statement Allegations: The lawsuit alleges that the company made materially false and misleading statements regarding its uranium enrichment technology prior to September 2024, raising approximately $18.6 million without actual testing, which could lead to severe losses for investors.
- Shareholder Rights Protection: Shareholders holding ASP Isotopes stock can seek corporate reforms and fund recovery at no cost, providing a legal remedy for affected investors that may influence the company's future governance structure.
- Market Reaction Potential: As the lawsuit progresses, market confidence in ASP Isotopes may be affected, leading to stock price volatility, prompting investors to closely monitor developments to assess potential financial impacts and investment risks.
See More
Faruqi & Faruqi Investigates Soleno Securities Fraud Claims
- Legal Investigation Launched: Faruq & Faruq LLP is investigating potential securities fraud claims against Soleno Therapeutics (NASDAQ: SLNO), particularly for investors who purchased securities between March 26 and November 4, 2025, urging them to seek lead plaintiff status by the May 5, 2026 deadline.
- Safety Concerns Exposed: The complaint alleges that Soleno and its executives violated federal securities laws by failing to disclose significant safety concerns related to the DCCR drug during clinical trials, including issues of fluid retention, which raises doubts about the drug's commercial viability and could impact future market performance.
- Stock Price Volatility: Following a critical report from Scorpion Capital on August 15, 2025, which raised serious concerns about DCCR's safety and efficacy, Soleno's stock price plummeted from $77 to $68 over two days, a nearly 12% decline; further, on September 10, the stock dropped 19% after a patient death was reported.
- Market Confidence Eroded: On November 4, 2025, Soleno reported third-quarter results indicating that the launch trajectory of DCCR had been disrupted, leading to fewer patient start forms and increased discontinuations, causing the stock to fall from $64 to $47 in a single day, a 27% drop that exacerbated investor concerns.
See More
Class Action Lawsuit Announced for Soleno Therapeutics
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit against Soleno Therapeutics (NASDAQ: SLNO) for stock purchasers between March 26 and November 4, 2025, aiming to seek compensation for investors, highlighting the legal risks and potential financial losses faced by the company.
- Reasons for Lawsuit: The lawsuit alleges that Soleno concealed significant safety concerns related to its DCCR drug clinical trials, including issues of fluid retention among participants, resulting in investor losses once the true information was disclosed, indicating a lack of transparency in the company's drug development processes.
- Investor Action Guidance: Investors can join the lawsuit by visiting a specified website or calling a hotline, reflecting the law firm's commitment to investor rights while also indicating uncertainty regarding Soleno's future commercial prospects.
- Law Firm Background: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling similar cases.
See More
Reminder of Securities Fraud Lawsuit Against Soleno Therapeutics
- Lawsuit Deadline: Investors must file a lead plaintiff motion in the securities fraud lawsuit against Soleno Therapeutics (SLNO) by May 5, 2026, for shares purchased between March 26, 2025, and November 4, 2026, or risk losing their claims.
- Stock Price Volatility: Following the August 15, 2025, release of a 415-page report by Scorpion Capital, Soleno's stock price dropped by $9.27, or 11.98%, over two days, indicating severe market concerns regarding the safety and efficacy of its drug.
- Adverse Event Disclosure: On September 10, 2025, Soleno reported a patient death linked to DCCR, causing the stock to fall by $13.49, or 19.21%, over two days, exacerbating investor losses and raising serious safety alarms.
- Financial Impact: The November 4, 2025, Q3 financial results revealed that the Scorpion report disrupted DCCR's launch, leading to fewer patient start forms and increased discontinuations, resulting in a stock price decline of $16.98, or 26.59%.
See More
Class Action Filed Against Soleno Therapeutics Over DCCR Disclosures
- Lawsuit Background: A securities class action lawsuit has been filed against Soleno Therapeutics (NASDAQ: SLNO) to represent investors who purchased common stock between March 26 and November 4, 2025, following a disappointing report on DCCR (trademarked as VYKAT™ XR) released on November 5, 2025.
- Stock Price Plunge: The report triggered a 26% drop in Soleno's stock price on the same day, reflecting strong market concerns about the company's future commercial prospects and prompting Hagens Berman to investigate potential violations of federal securities laws.
- Safety Concerns: The lawsuit alleges that Soleno systematically downplayed and concealed significant safety risks associated with DCCR, particularly issues related to fluid retention in clinical trial participants, which could materially lower the drug's commercial viability.
- Eroded Market Confidence: Since August 15, 2025, Soleno's stock has fallen nearly 40%, with management acknowledging during the Q3 2025 earnings call that the short seller report disrupted their launch trajectory, further undermining investor confidence.
See More
Securities Fraud Class Action Filed Against Soleno Therapeutics, Inc.
- Lawsuit Background: On March 14, 2026, Kessler Topaz Meltzer & Check, LLP filed a securities fraud class action against Soleno Therapeutics, Inc. for investors who purchased common stock between March 26 and November 4, 2025, highlighting serious concerns regarding the company's financial transparency.
- Safety Concerns Disclosure: The lawsuit alleges that Soleno concealed significant safety issues related to its DCCR drug during Phase 3 clinical trials, including fluid retention in participants, which raised doubts about the drug's commercial viability and negatively impacted the company's market credibility.
- Stock Price Plunge: Following the financial results announcement on November 4, 2025, Soleno's stock price dropped over 26% due to negative revelations linked to the Scorpion Capital report, indicating a pessimistic market sentiment regarding the company's future prospects.
- Investor Action Recommendation: Soleno investors are encouraged to apply for lead plaintiff status in the class action by May 5, 2026, demonstrating their proactive stance in legal rights protection and concern for corporate governance issues.
See More
ASP Isotopes Class Action Survives Dismissal Motion
- Class Action Progress: The class action against ASP Isotopes Inc. (NASDAQ: ASPI) survives a partial dismissal motion in the Southern District of New York, indicating that securities fraud allegations against the company and its executives remain valid, potentially exposing the company to significant legal liabilities.
- False Statement Allegations: The lawsuit alleges that the company made materially false and misleading statements regarding its uranium enrichment technology prior to September 2024, raising approximately $18.6 million without actual testing, which could lead to severe losses for investors.
- Shareholder Rights Protection: Shareholders holding ASP Isotopes stock can seek corporate reforms and fund recovery at no cost, providing a legal remedy for affected investors that may influence the company's future governance structure.
- Market Reaction Potential: As the lawsuit progresses, market confidence in ASP Isotopes may be affected, leading to stock price volatility, prompting investors to closely monitor developments to assess potential financial impacts and investment risks.
See More
Faruqi & Faruqi Investigates Soleno Securities Fraud Claims
- Legal Investigation Launched: Faruq & Faruq LLP is investigating potential securities fraud claims against Soleno Therapeutics (NASDAQ: SLNO), particularly for investors who purchased securities between March 26 and November 4, 2025, urging them to seek lead plaintiff status by the May 5, 2026 deadline.
- Safety Concerns Exposed: The complaint alleges that Soleno and its executives violated federal securities laws by failing to disclose significant safety concerns related to the DCCR drug during clinical trials, including issues of fluid retention, which raises doubts about the drug's commercial viability and could impact future market performance.
- Stock Price Volatility: Following a critical report from Scorpion Capital on August 15, 2025, which raised serious concerns about DCCR's safety and efficacy, Soleno's stock price plummeted from $77 to $68 over two days, a nearly 12% decline; further, on September 10, the stock dropped 19% after a patient death was reported.
- Market Confidence Eroded: On November 4, 2025, Soleno reported third-quarter results indicating that the launch trajectory of DCCR had been disrupted, leading to fewer patient start forms and increased discontinuations, causing the stock to fall from $64 to $47 in a single day, a 27% drop that exacerbated investor concerns.
See More
Class Action Lawsuit Announced for Soleno Therapeutics
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit against Soleno Therapeutics (NASDAQ: SLNO) for stock purchasers between March 26 and November 4, 2025, aiming to seek compensation for investors, highlighting the legal risks and potential financial losses faced by the company.
- Reasons for Lawsuit: The lawsuit alleges that Soleno concealed significant safety concerns related to its DCCR drug clinical trials, including issues of fluid retention among participants, resulting in investor losses once the true information was disclosed, indicating a lack of transparency in the company's drug development processes.
- Investor Action Guidance: Investors can join the lawsuit by visiting a specified website or calling a hotline, reflecting the law firm's commitment to investor rights while also indicating uncertainty regarding Soleno's future commercial prospects.
- Law Firm Background: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling similar cases.
See More
Reminder of Securities Fraud Lawsuit Against Soleno Therapeutics
- Lawsuit Deadline: Investors must file a lead plaintiff motion in the securities fraud lawsuit against Soleno Therapeutics (SLNO) by May 5, 2026, for shares purchased between March 26, 2025, and November 4, 2026, or risk losing their claims.
- Stock Price Volatility: Following the August 15, 2025, release of a 415-page report by Scorpion Capital, Soleno's stock price dropped by $9.27, or 11.98%, over two days, indicating severe market concerns regarding the safety and efficacy of its drug.
- Adverse Event Disclosure: On September 10, 2025, Soleno reported a patient death linked to DCCR, causing the stock to fall by $13.49, or 19.21%, over two days, exacerbating investor losses and raising serious safety alarms.
- Financial Impact: The November 4, 2025, Q3 financial results revealed that the Scorpion report disrupted DCCR's launch, leading to fewer patient start forms and increased discontinuations, resulting in a stock price decline of $16.98, or 26.59%.
See More
Class Action Filed Against Soleno Therapeutics Over DCCR Disclosures
- Lawsuit Background: A securities class action lawsuit has been filed against Soleno Therapeutics (NASDAQ: SLNO) to represent investors who purchased common stock between March 26 and November 4, 2025, following a disappointing report on DCCR (trademarked as VYKAT™ XR) released on November 5, 2025.
- Stock Price Plunge: The report triggered a 26% drop in Soleno's stock price on the same day, reflecting strong market concerns about the company's future commercial prospects and prompting Hagens Berman to investigate potential violations of federal securities laws.
- Safety Concerns: The lawsuit alleges that Soleno systematically downplayed and concealed significant safety risks associated with DCCR, particularly issues related to fluid retention in clinical trial participants, which could materially lower the drug's commercial viability.
- Eroded Market Confidence: Since August 15, 2025, Soleno's stock has fallen nearly 40%, with management acknowledging during the Q3 2025 earnings call that the short seller report disrupted their launch trajectory, further undermining investor confidence.
See More
